-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Tcr2 Therapeutics Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2019 to 2022.
- Tcr2 Therapeutics Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2023 was $0.000, a 100% decline year-over-year.
- Tcr2 Therapeutics Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$293K, a 396% decline from 2021.
- Tcr2 Therapeutics Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $99K, a 24.4% decline from 2020.
- Tcr2 Therapeutics Inc. annual Deferred Income Tax Expense (Benefit) for 2020 was $131K, a 111% increase from 2019.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)